Insights On Downstream Manufacturing

  1. Designing ADC Manufacturing For Operator And Patient Safety 11/6/2026

    ADC manufacturing succeeds when manufacturability is treated as an early design input. Cell line choices, toxic payload handling, and single-use extractables each shape operator exposure and risk.

  2. Advancing Downstream Bioprocessing With Single-Use Solutions 11/6/2026

    Closed, configurable single-use fluid management between downstream steps can influence how flexible, efficient, and agile a bioprocess is, from early development through commercial production.

  3. The Critical Role Of Integrated Handling Design 11/5/2026

    Unplanned downtime and inconsistent throughput on syringe and injectable lines often trace back to handling design. System-level thinking about transport changes where performance is decided.

  4. Rethinking Facility Design For The Reality Of Complex Biologics 11/4/2026

    Inert surface technologies reduce metal-related adsorption in chromatography, improving peak shape, recovery, sensitivity, and quantitation for more reliable analytical results.

  5. How Automation Can Facilitate Annex 1 Compliance In Final Filtration 11/3/2026

    Annex 1 expectations for PUPSIT expose how much risk sits in operator-dependent final filtration, and why automation, assembly design, and product recovery now shape compliance decisions.

  6. Simtra Biopharma Solutions Capabilities Update October 2026: Fill Finish 11/3/2026

    Explore new sterile manufacturing capacity for pre-filled syringes, lyophilized vials, and potent therapies, supporting flexibility, scale, and supply resilience.

  7. Alcami Capabilities Update October 2026: Fill Finish 11/3/2026

    Discover critical considerations for sterile fill-finish, including manufacturability, scale-up, contamination control, and the path from clinical to commercial supply.

  8. Advances In ADC Development And Manufacturing 11/3/2026

    ADC manufacturability starts at molecule design, not downstream rescue. Learn how operator exposure to high-potency payloads shapes how conjugation workflows are built and qualified.

  9. The People Behind The Process: How Teams Enable Flexible Manufacturing 11/2/2026

    Biopharma demands flexibility across specialty and high-volume products. The right equipment, automation, and teams enable partners to pivot without compromising quality.

  10. Lonza Capabilities Update October 2026: Fill/Finish 11/2/2026

    Bastian Klöfer, Director of Commercial Development, Drug Product Services, explores Lonza's end-to-end biologics network, spanning drug substance, drug product development, manufacturing, analytics and regulatory support.